Ratings by Rodman & Renshaw (Michael King Jr.)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/30/2026 | Actuate Therapeutics | ACTU | New Coverage | Buy (N/A) |
1.08 (1.09) |
0.93% | Details | |
| 7/7/2026 | Atossa Genetics | ATOS | New Coverage | Buy (N/A) |
2.28 (2.41) |
5.7% | Details | |
| 6/30/2026 | vTv Therapeutics | VTVT | New Coverage | Buy (N/A) |
36.27 (34.51) |
-4.85% | Details | |
| 6/15/2026 | Elicio Therapeutics | ELTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | Kyntra Bio | KYNB | New Coverage | Buy (N/A) |
6.63 (7.18) |
8.3% | Details | |
| 5/28/2026 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Buy (N/A) |
5.28 (4.03) |
-23.67% | Details | |
| 5/11/2026 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
3.51 (3.64) |
3.7% | Details | |
| 4/15/2026 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
3.15 (2.13) |
-32.38% | Details | |
| 3/17/2026 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
1.54 (0.92) |
-40.26% | Details | |
| 3/9/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Buy (N/A) |
8.77 (1.95) |
-77.77% | Details | |
| 3/9/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.63 (3.07) |
-73.6% | Details | |
| 1/13/2026 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
1.35 (1.16) |
-14.07% | Details | |
| 1/13/2026 | Ascentage Pharma Group | AAPG | New Coverage | Buy (N/A) |
28.38 (18.86) |
-33.54% | Details | |
| 1/13/2026 | Biomea Fusion Inc. | BMEA | New Coverage | Buy (N/A) |
1.46 (1.27) |
-13.01% | Details | |
| 1/13/2026 | BioAtla Inc. | BCAB | New Coverage | Buy (N/A) |
0.31 (3.52) |
1035.48% | Details | |
| 1/13/2026 | Jasper Therapeutics | JSPR | New Coverage | Buy (N/A) |
1.48 (0.79) |
-46.62% | Details |
